These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 3410355)

  • 1. Use of a murine model for comparison of intravenous and intraperitoneal cisplatin in the treatment of microscopic ovarian cancer.
    Mannel RS; Stratton JA; Rettenmaier MA; Liao SY; DiSaia PJ
    Gynecol Oncol; 1988 Sep; 31(1):50-5. PubMed ID: 3410355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Survival Analysis of Intraperitoneal versus Intravenous Chemotherapy for Primary Ovarian Cancer and Comparison between Carboplatin- and Cisplatin-based Intraperitoneal Chemotherapy.
    Eoh KJ; Lee JY; Nam EJ; Kim S; Kim YT; Kim SW
    J Korean Med Sci; 2017 Dec; 32(12):2021-2028. PubMed ID: 29115086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer.
    Markman M; Reichman B; Hakes T; Rubin S; Lewis JL; Jones W; Barakat R; Curtin J; Almadrones L; Hoskins W
    Gynecol Oncol; 1993 Jul; 50(1):100-4. PubMed ID: 8349150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group.
    Markman M; Bundy BN; Alberts DS; Fowler JM; Clark-Pearson DL; Carson LF; Wadler S; Sickel J
    J Clin Oncol; 2001 Feb; 19(4):1001-7. PubMed ID: 11181662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look.
    Makhija S; Sabbatini P; Aghajanian C; Venkatraman E; Spriggs DR; Barakat R
    Gynecol Oncol; 2000 Oct; 79(1):28-32. PubMed ID: 11006026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [An experiment control study on the ovarian reserve function after cisplatin intraperitoneal or intravenous chemotherapy in rats model].
    Fan BZ; Xia H; Chu L; Tong XW
    Zhonghua Fu Chan Ke Za Zhi; 2017 Apr; 52(4):249-253. PubMed ID: 28441841
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of the intraperitoneal and intravenous routes of cisplatin administration in an advanced ovarian cancer model of the rat.
    Sekiya S; Iwasawa H; Takamizawa H
    Am J Obstet Gynecol; 1985 Sep; 153(1):106-11. PubMed ID: 4041136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
    Barlin JN; Dao F; Bou Zgheib N; Ferguson SE; Sabbatini PJ; Hensley ML; Bell-McGuinn KM; Konner J; Tew WP; Aghajanian C; Chi DS
    Gynecol Oncol; 2012 Jun; 125(3):621-4. PubMed ID: 22446622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Study of Antitumor Efficiency of Intraperitoneal and Intravenous Cytostatics in Experimental Rats with Disseminated Ovarian Cancer.
    Bespalov VG; Vyshinskaya EA; Vasil'eva IN; Semenov AL; Maidin MA; Barakova NV; Stukov AN
    Bull Exp Biol Med; 2017 Jan; 162(3):383-386. PubMed ID: 28091920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
    Gray HJ; Shah CA; Swensen RE; Tamimi HK; Goff BA
    Gynecol Oncol; 2010 Mar; 116(3):340-4. PubMed ID: 19922987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.
    Bristow RE; Santillan A; Salani R; Diaz-Montes TP; Giuntoli RL; Meisner BC; Armstrong DK; Frick KD
    Gynecol Oncol; 2007 Sep; 106(3):476-81. PubMed ID: 17688927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
    Armstrong DK; Bundy B; Wenzel L; Huang HQ; Baergen R; Lele S; Copeland LJ; Walker JL; Burger RA;
    N Engl J Med; 2006 Jan; 354(1):34-43. PubMed ID: 16394300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer.
    Suidan RS; St Clair CM; Lee SJ; Barlin JN; Long Roche KC; Tanner EJ; Sonoda Y; Barakat RR; Zivanovic O; Chi DS
    Gynecol Oncol; 2014 Sep; 134(3):468-72. PubMed ID: 25042672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer.
    Bouchard-Fortier G; Rosen B; Vyarvelska I; Pasetka M; Covens A; Gien LT; Kupets R; Pulman K; Ferguson SE; Vicus D
    Gynecol Oncol; 2016 Jan; 140(1):36-41. PubMed ID: 26546964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraperitoneal cisplatin chemotherapy versus abdominopelvic irradiation in ovarian carcinoma patients after second-look laparotomy.
    Menczer J; Ben-Baruch G; Modan M; Brenner H
    Cancer; 1989 Apr; 63(8):1509-13. PubMed ID: 2924259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer.
    Yen MS; Juang CM; Lai CR; Chao GC; Ng HT; Yuan CC
    Int J Gynaecol Obstet; 2001 Jan; 72(1):55-60. PubMed ID: 11146078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse models.
    Ye H; Tanenbaum LM; Na YJ; Mantzavinou A; Fulci G; Del Carmen MG; Birrer MJ; Cima MJ
    J Control Release; 2015 Dec; 220(Pt A):358-367. PubMed ID: 26548976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ip cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the iv route.
    Casper ES; Kelsen DP; Alcock NW; Lewis JL
    Cancer Treat Rep; 1983 Mar; 67(3):235-8. PubMed ID: 6682012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy.
    Esselen KM; Rodriguez N; Growdon W; Krasner C; Horowitz NS; Campos S
    Gynecol Oncol; 2012 Oct; 127(1):51-4. PubMed ID: 22659193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Front-line intraperitoneal versus intravenous chemotherapy in stage III-IV epithelial ovarian, tubal, and peritoneal cancer with minimal residual disease: a competing risk analysis.
    Chang YH; Li WH; Chang Y; Peng CW; Cheng CH; Chang WP; Chuang CM
    BMC Cancer; 2016 Mar; 16():235. PubMed ID: 26988703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.